Skip to main content
Metabolism Open logoLink to Metabolism Open
editorial
. 2022 Jan 19;13:100164. doi: 10.1016/j.metop.2022.100164

The non-linear relationship between muscle mass and BMI calls into question the use of BMI as a major criterion for eligibility for bariatric surgery

Junli Liu 1,, Dimitrios Tsilingiris 2, Maria Dalamaga 3
PMCID: PMC8800132  PMID: 35118366

Type 2 diabetes mellitus (T2DM) is a growing health problem worldwide, largely because of the high burden of increasing obesity rates [[1], [2], [3]]. In comparison with intensive medical therapy, Roux-en-Y gastric bypass (RYGB) surgery is a particularly effective intervention for T2DM, with about 60% of obese individuals achieving T2DM remission (DR) and sustained weight loss [4,5]. Several predictive factors for DR have been identified, including age, disease duration, glycemic control, and insulin usage [6,7]. However, the predictive performance of existing methods is modest, especially for patients in the lower BMI range (<30 kg/m2) who show considerably poorer remission rates (range, 30%–40%) [8]. In addition, one-third of patients who underwent RYGB showed relapse within 5 years of initial remission [4]. Thus, novel DR-related factors are required in order to optimize preoperative evaluation and postoperative management. Indeed, the use of bariatric surgery worldwide is largely governed by a 1991 National Institutes of Health consensus statement that advocated BMI-based operative criteria [9], even though no direct evidence has been obtained to support the ability of BMI to predict DR after surgery [10,11]. One important but underexplored methodological limitation of this approach is that BMI does not discriminate between fat mass and fat-free mass (FFM). Skeletal muscle is the major component of FFM [12] and plays a critical role in whole-body glucose homeostasis [13].

A very recent study by Li et al. published in Diabetes Care [14] has revealed the potential relevance of muscle mass assessed by magnetic resonance imaging (MRI) or a predictive equation on BMI limitations in predicting DR after RYGB. It is concluded that a two-phase association exists between muscle mass and BMI and baseline muscle mass or estimated fat-free mass index (eFFMI) are associated with short- and long-term DR after RYGB.

Previous studies had reported that individuals with higher BMIs have a larger skeletal muscle mass and fat mass, and the relationship between BMI and body component was thought to show a positive correlation [15]. In this study, the authors firstly provided compelling new evidence for the limitations of BMI in assessing body composition, with the muscle mass showing a significant threshold effect with increasing body weight (BMI cut-off = 31.88 for males and 32.66 for females). Similarly, at the inflection point (BMI = 33.71 for males and 33.91 for females), the increment in visceral fat changed despite not being statistically significant (P = 0.12) in males and being significant in females (P = 0.022). In contrast, subcutaneous fat did not show a breakpoint, which may be attributed to its larger capacity limit. These results indicated that a single BMI value cannot adequately reflect the dynamics of body composition, especially muscle mass. Next, in the longitudinal study for DR with a 5-year follow-up RYGB surgical cohort, psoas cross-sectional area and eFFMI were strong predictors for 1- and 5-year DR after RYGB surgery in Chinese T2DM patients, but BMI did not show such predictive ability. The presence of more muscle mass before surgery indicates a greater possibility of achieving complete DR after surgery.

In conclusion, the non-linear relationship between muscle mass and BMI may explain why BMI cannot adequately predict DR after surgery. The difference in DR rates between the high-BMI (>30 kg/m2) and low-BMI populations reported in previous studies may be attributed to the differences in muscle mass between the two groups. This study (along with other published studies) call into question the rationale in using BMI as a criterion for eligibility for bariatric surgery. Predicted FFMI may be a simple parameter superior to BMI to be included in clinical guidelines for preoperative evaluation of bariatric surgery in the future. The fact that the study participants originated from a single ethnic group may in part limit the immediate generalizability of the results, at least until these are validated in other populations as well. Nevertheless, the findings are novel and offer valuable insight into potentially useful prognostic markers for successful diabetes remission in patients with obesity.

Funding information

None.

Declaration of competing interest

None.

Contributor Information

Junli Liu, Email: liujunli@sjtu.edu.cn.

Maria Dalamaga, Email: madalamaga@med.uoa.gr.

References

  • 1.Vallianou N.G., Geladari E.V., Kounatidis D., Geladari C.V., Stratigou T., Dourakis S.P., Andreadis E.A., Dalamaga M. Diabetes mellitus in the era of climate change. Diabetes Metab. 2021;47(4):101205. doi: 10.1016/j.diabet.2020.10.003. [DOI] [PubMed] [Google Scholar]
  • 2.Tsilingiris D., Vallianou N.G., Dalamaga M. Prediabetes screening: questionable benefits in the golden years. Metabol Open. 2021;10:100091. doi: 10.1016/j.metop.2021.100091. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Koliaki C., Liatis S., Dalamaga M., Kokkinos A. Sarcopenic obesity: epidemiologic evidence, pathophysiology, and therapeutic perspectives. Curr Obes Rep. 2019;8(4):458–471. doi: 10.1007/s13679-019-00359-9. [DOI] [PubMed] [Google Scholar]
  • 4.McTigue K.M., Wellman R., Nauman E., et al. Comparing the 5-year diabetes outcomes of sleeve gastrectomy and gastric bypass: the National Patient-Centered Clinical Research Network (PCORNet) bariatric study. JAMA Surg. 2020 doi: 10.1001/jamasurg.2020.0087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Schauer P.R., Kashyap S.R., Wolski K., et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012;366(17):1567–1576. doi: 10.1056/NEJMoa1200225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Wang G.F., Yan Y.X., Xu N., et al. Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg. 2015;25(2):199–208. doi: 10.1007/s11695-014-1391-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Dixon J.B., Chuang L.M., Chong K., et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36(1):20–26. doi: 10.2337/dc12-0779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Baskota A., Li S., Dhakal N., Liu G., Tian H. Bariatric surgery for type 2 diabetes mellitus in patients with BMI <30 kg/m2: a systematic review and meta-analysis. PLoS One. 2015;10(7) doi: 10.1371/journal.pone.0132335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.NIH conference Gastrointestinal surgery for severe obesity. Consensus Development Conference panel. Ann Intern Med. 1991;115(12):956–961. [PubMed] [Google Scholar]
  • 10.Cummings D.E., Cohen R.V. Bariatric/Metabolic surgery to treat type 2 diabetes in patients with a BMI <35 kg/m2. Diabetes Care. 2016;39(6):924–933. doi: 10.2337/dc16-0350. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Cummings D.E., Cohen R.V. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol. 2014;2(2):175–181. doi: 10.1016/S2213-8587(13)70198-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Davidson L.E., Yu W., Goodpaster B.H., et al. Fat-free mass and skeletal muscle mass five years after bariatric surgery. Obesity. 2018;26(7):1130–1136. doi: 10.1002/oby.22190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yokoyama I., Inoue Y., Moritan T., Ohtomo K., Nagai R. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET. J Nucl Med: Off Publ, Soc Nucl Med. 2003;44(10):1592–1598. [PubMed] [Google Scholar]
  • 14.Li S., Yu H., Zhang P., et al. The nonlinear relationship between psoas cross-sectional area and BMI: a new observation and its insights into diabetes remission after Roux-en-Y gastric bypass. Diabetes Care. 2021;44(12):2783–2786. doi: 10.2337/dc20-2907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Lee D.H., Keum N., Hu F.B., et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study. Br Med J. 2018;362:k2575. doi: 10.1136/bmj.k2575. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Metabolism Open are provided here courtesy of Elsevier

RESOURCES